Publications by authors named "I E G van Hellemond"
Background: The FLOT4 trial demonstrated superior survival of perioperative chemotherapy with 5-fluorouracil, oxaliplatin, and docetaxel (FLOT) compared to anthracycline triplets for resectable gastric cancer. These results were presented at the American Society of Clinical Oncology (ASCO) congress in June 2017 and published in April 2019. However, adoption of novel treatments in clinical practice often encounters delays.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates the interactions between the chemotherapy drug capecitabine (CAP) and gut microbiota in colorectal cancer patients, focusing on how these interactions may affect treatment side effects.
- Research involved a cohort of 56 patients, analyzing stool samples and using advanced sequencing techniques to observe changes in gut microbial composition during CAP treatment.
- Findings indicate that CAP alters gut bacteria, promoting genes related to vitamin K2 production, which appears to protect against drug toxicity, suggesting potential for microbiome profiling to predict chemotherapy side effects.
In patients with resectable colorectal peritoneal metastases, it is unclear whether systemic chemotherapy, in addition to cytoreductive surgery-hyperthermic intraperitoneal chemotherapy (CRS-HIPEC), improves overall survival (OS). This systematic review of 12 retrospective studies involving 3721 patients aimed to summarize the available evidence. Contradictory results were found regarding the effectiveness of neoadjuvant, adjuvant, and perioperative systemic therapies on OS, with a high risk of bias.
View Article and Find Full Text PDFPurpose: Patients with chemotherapy-induced ovarian function failure (CIOFF) may experience ovarian function recovery (OFR). Earlier, we showed that OFR during treatment with anastrozole impacted the prognosis of hormone receptor-positive (HR+) breast cancer (BC) patients with CIOFF. Here, we present the long-term follow-up results.
View Article and Find Full Text PDFDue to improvements in treatment for primary rectal cancer, the incidence of LRRC has decreased. However, 6-12% of patients will still develop a local recurrence. Treatment of patients with LRRC can be challenging, because of complex and heterogeneous disease presentation and scarce - often low-grade - data steering clinical decisions.
View Article and Find Full Text PDF